secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2026-08-25T14:54:11+00:00
Accession:  0001937653-26-000051
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves zanidatamab combo for HER2+ GEA; Zymeworks earns $250M milestone
-----------------------------------------------------------------------------

- FDA approval of Ziihera (zanidatamab-hrii) with/without tislelizumab plus chemo in first-line HER2+ GEA triggers $250M milestone from Jazz.
- Zymeworks has now received $650M total upfront and milestone payments from Jazz; remains eligible for up to $1.3B more and 10-20% royalties.
- BeOne collaboration: $81M received to date; up to $144M additional milestones plus up to 19.5% royalties on sales.
- Approval based on Phase 3 HERIZON-GEA-01 trial (published in NEJM); second FDA approval for zanidatamab in under two years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765326000051/0001937653-26-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765326000051/zyme-20260825.htm
  HTML page:      https://secwatch.observer/filing/0001937653-26-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer